In addition, increasing studies have reported a role for type I IFNs (interferons) in the pathogenesis of different subsets of RA patients, indicating that IFN-α/βactivity may have essential clinical utility in predicting response to tumor necrosis factor antagonists (35–37). The gene discussed is TNF; the disease is rheumatoid arthritis.